Difference between revisions of "Buparlisib (BKM-120)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Chemotherapy" to "Category:Chemotherapeutic") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Investigational" to "Category:Investigational drugs") |
||
| Line 13: | Line 13: | ||
[[Category:PI3K inhibitors]] | [[Category:PI3K inhibitors]] | ||
| − | [[Category:Investigational]] | + | [[Category:Investigational drugs]] |
Revision as of 18:08, 3 February 2019
Mechanism of action
Orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases
Preliminary data
Head and neck cancer
- Soulières D, Faivre S, Mesía R, Remenár É, Li SH, Karpenko A, Dechaphunkul A, Ochsenreither S, Kiss LA, Lin JC, Nagarkar R, Tamás L, Kim SB, Erfán J, Alyasova A, Kasper S, Barone C, Turri S, Chakravartty A, Chol M, Aimone P, Hirawat S, Licitra L. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. 2017 Mar;18(3):323-335. Epub 2017 Jan 26. link to original article PubMed